Calando Aims to Complete RNAi Phase I Trial, Ink Development Partnership by Year's End

The CEO of Calando parent firm Arrowhead Research also said that the RNAi shop has restarted preclinical research and development — a notable departure from events in 2009 when the company stopped all such work and shuttered Calando's lab amid a cash crunch.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.